Your assay’s reference interval was established elsewhere—here’s how to verify it locally with just 20 samples, not a clinical trial.
The most practical, universally accepted method is a local verification study using a small cohort of healthy individuals. According to standard CLSI protocols, you need only 20 reference subjects. If no more than two of their test results (10%) fall outside the proposed upper or lower limits, the transferred interval is considered validated for your population and instrument system. This simple approach confirms analytical calibration consistency and population comparability without the cost or time of a full reference interval trial.
The heart of reference interval transfer is a pragmatic 20-sample check: if ≤2 values fall outside the limits, you’re verified. But this quick test has a blind spot—it won't warn you when your true local range is narrower than the borrowed one. Pair it with retrospective data mining to catch that risk.
Why a Full Clinical Trial Usually Isn’t Necessary
Reference intervals from an IVD manufacturer’s package insert or a robust multicenter study already carry substantial validation weight. You’re not starting from zero.
The Scientific Premise of Transferability
The intervals were derived using well-characterized reference populations and standardized analytical systems. If your assay system is analytically identical (same reagents, calibrators, and platform) and your target population is demographically comparable, you are essentially confirming equivalence, not creating new normative ranges.
Regulatory and Guideline Alignment
CLSI document EP28-A3c explicitly endorses the transfer-and-verify approach. Regulatory bodies accept this small-scale verification because it is a focused risk mitigation step, not a de novo experiment. It conserves resources while still providing a statistically valid gate.
The Core Protocol: 20 Samples, One Clear Criterion
The method is designed to be executable by any clinical laboratory or assay developer.
Step 1: Selecting Your 20 Reference Individuals
Careful selection is more important than the number. You must recruit healthy individuals who mirror your intended patient population in age, sex, and, if relevant, ethnicity and environmental factors. Exclude anyone with conditions that influence the analyte, use of interfering medications, or any acute illness.
Step 2: Testing Under Real-World Conditions
Run the samples on your exact end-user instrument, using the identical reagents, calibrators, and preanalytical protocols that will be used for patient testing. The goal is to validate the entire local analytical ecosystem, not just the assay chemistry.
Step 3: The 2-out-of-20 (10%) Rule
Apply the manufacturer’s proposed reference limits to your 20 results. If two or fewer values fall outside the limits, the interval passes verification. If three or more fail, the interval is rejected for your setting. This is not an arbitrary threshold; it is built on a statistical framework that balances sensitivity with practicality.
Beyond the 20-Patient Gate: Strengthening Your Confidence
Passing the 2-of-20 test gives you a green light, but you can layer on low-cost surveillance to make your verification even more robust over time.
The Hidden Flaw One Test Doesn’t Catch
A passed 20-sample verification can still miss a critical problem: your local healthy population’s true reference range might be significantly narrower than the manufacturer’s. This means some truly abnormal patients could hide inside a broad “normal” interval, or you could misclassify normal results as borderline.
Pairing Verification with Data Mining
After initial verification, continuously monitor your outpatient results. Track the median value and the percentage of results outside the limits. For a stable, healthy outpatient population, the median should sit near the midpoint of the reference interval, and few healthy results should flag. If the median drifts or outliers increase, investigate analytical drift or reagent lot changes—and consider re-running a confirmatory 20-sample check.
Understanding the Trade-offs
No method is perfect. Transparency about the limitations of a transferred interval builds sound clinical judgment.
The Limits of a Small Sample Size
A 20-subject study lacks the statistical power to fully characterize your local distribution’s tails. It cannot prove your 2.5th and 97.5th percentiles exactly match the transferred ones. You are making a calculated trade-off: practicality and speed in exchange for a small risk of misclassification at the fuzzy edges of “normal.”
When the “Transfer” Model Breaks
Transfer is inappropriate if:
- Your patient population is demographically distinct (e.g., a vastly different ethnic group or specialized pediatric cohort).
- Your analytical system is meaningfully different from the one used to establish the interval.
- The analyte shows significant biological variation linked to geography, diet, or lifestyle not captured in the original study.
In any of these cases, a small verification study is insufficient; you must conduct a full, independent reference interval establishment study.
Making the Right Choice for Your Goal
How you approach verification depends on your primary need—speed, risk management, or long-term stability.
- If your primary focus is minimal resource drain: Execute the 20-sample verification directly per the protocol. This is the cheapest, fastest path to compliance and operational go-live.
- If your primary focus is detecting subtle population mismatches: Complement the initial 20-sample test with ongoing data mining of outpatient medians and outlier rates. This will surface hidden shifts over months, not days.
- If your primary focus is high-risk analytes or vulnerable populations: Do not rely solely on transfer. Invest in a larger pilot study or consult a biostatistician to determine if a full reference interval study is warranted based on demographic deviation.
A transferred reference interval is a proven, safe starting point—when you verify it thoughtfully and keep one eye on the data long after the initial 20 samples are run.
Summary Table:
| Phase | Key Protocol Action | Pass Criteria / Risk Control |
|---|---|---|
| Sample Selection | Recruit 20 healthy reference individuals | Demographically matched; exclude confounders |
| Analytical Testing | Run tests under local real-world conditions | Identical instruments, reagents, and calibrators |
| Verification Gate | Apply proposed limits (CLSI EP28-A3c) | ≤ 2 out of 20 values (≤ 10%) outside limits |
| Ongoing Surveillance | Perform retrospective outpatient data mining | Track medians and outlier trends to catch narrow ranges |
Streamline Your IVD Development with CamelBio
Transitioning assays from concept to clinical adoption requires precision, reliability, and speed. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Whether you need top-tier assay reagents or specialized validation guidance, our team is here to support your success. Contact us today to discuss your project requirements!